Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

This recent FORMA/Oxford collaboration brings together Oxford’s expertise in disease molecular pathology and Ubiquitin biology, (including through the Alzheimer’s Research UK Oxford Drug Discovery Institute (ODDI), the Target Discovery Institute (TDI) and the Oxford Parkinson’s Disease Centre (OPDC)), and FORMA’s deep expertise in small molecule drug design and development

Similar stories

New vaccine trial for Middle East Respiratory Syndrome launched

A new clinical trial to find a vaccine to protect people against Middle East Respiratory Syndrome (MERS) launched on 15 September 2023. This is the third Phase I clinical trial of the ChAdOx1 MERS vaccine, developed by researchers at the Pandemic Sciences Institute. It is the first trial in older people.